164 related articles for article (PubMed ID: 2407364)
1. The clinical role of OKT3.
Norman DJ
Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
[TBL] [Abstract][Full Text] [Related]
2. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
Norman DJ
Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
[TBL] [Abstract][Full Text] [Related]
3. [The immunobiology of transplant rejection and its pharmacological modification].
Köhler H; Zanker B; Strom TB
Dtsch Med Wochenschr; 1991 Feb; 116(7):264-9. PubMed ID: 1825196
[No Abstract] [Full Text] [Related]
4. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
5. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
7. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
8. [T lymphocyte activation induced in vivo by the first injection of OKT3 monoclonal antibodies].
Chatenoud L; Ferran C; Reuter A; Legendre C; Gevaert Y; Kreis H; Franchimont P; Bach JF
C R Acad Sci III; 1988; 307(19):833-6. PubMed ID: 3146414
[TBL] [Abstract][Full Text] [Related]
9. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
10. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
[No Abstract] [Full Text] [Related]
11. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
12. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
Li PK; Nicholls MG; Lai KN
Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
[No Abstract] [Full Text] [Related]
13. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
14. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
J Immunol; 1993 Jun; 150(11):5163-74. PubMed ID: 7684422
[TBL] [Abstract][Full Text] [Related]
15. Anti-Leu2a (anti-CD8) monoclonal antibody therapy: antibody-mediated cell clearance in vivo requires Fc-FcRII interaction.
Wee SL; Phelan JM; Preffer FI; Colvin RB; Cosimi AB
Transplant Proc; 1989 Feb; 21(1 Pt 1):117-8. PubMed ID: 2495592
[No Abstract] [Full Text] [Related]
16. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
[No Abstract] [Full Text] [Related]
17. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
[No Abstract] [Full Text] [Related]
18. The role of OKT3 in clinical transplantation.
Norman DJ; Leone MR
Pediatr Nephrol; 1991 Jan; 5(1):130-6. PubMed ID: 1827342
[TBL] [Abstract][Full Text] [Related]
19. [Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host].
Debure A; Chkoff N; Chatenoud L; Lacombe M; Campos H; Noël LH; Goldstein G; Bach JF; Kreis H
Nephrologie; 1987; 8(3):87-94. PubMed ID: 3116443
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
